JP2025506671A - ブルトン型チロシンキナーゼ阻害剤の合成 - Google Patents

ブルトン型チロシンキナーゼ阻害剤の合成 Download PDF

Info

Publication number
JP2025506671A
JP2025506671A JP2024547937A JP2024547937A JP2025506671A JP 2025506671 A JP2025506671 A JP 2025506671A JP 2024547937 A JP2024547937 A JP 2024547937A JP 2024547937 A JP2024547937 A JP 2024547937A JP 2025506671 A JP2025506671 A JP 2025506671A
Authority
JP
Japan
Prior art keywords
compound
hours
solvent
base
reaction mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547937A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506671A5 (https=
Inventor
ダック トラン，ゴック
シオウラス，クリストス
クリーター，エドワード
マトン，ウィリアム，マーク
ヨアヒム ランドワルド ランメルー，トーマス
フェルナンデス，フィリップ
ピエール エー ボンガルツ，ジャン
チ チュン カオ，ズイ
アラン ホロウィッツ，マシュー
ジャン－マリー ジュシュー，グザヴィエ
フランソワ エマニュエル ルメール，セバスチャン
シュバイツァー－シャプー，バートランド
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2025506671A publication Critical patent/JP2025506671A/ja
Publication of JP2025506671A5 publication Critical patent/JP2025506671A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Health & Medical Sciences (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pyridine Compounds (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2024547937A 2022-02-18 2023-02-17 ブルトン型チロシンキナーゼ阻害剤の合成 Pending JP2025506671A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GR20220100151 2022-02-18
GR20220100151 2022-02-18
EP22167032 2022-04-06
EP22167032.6 2022-04-06
EP22178413.5 2022-06-10
EP22178413 2022-06-10
PCT/EP2023/054043 WO2023156599A1 (en) 2022-02-18 2023-02-17 Synthesis of bruton's tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2025506671A true JP2025506671A (ja) 2025-03-13
JP2025506671A5 JP2025506671A5 (https=) 2026-02-18

Family

ID=85227338

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547937A Pending JP2025506671A (ja) 2022-02-18 2023-02-17 ブルトン型チロシンキナーゼ阻害剤の合成

Country Status (13)

Country Link
US (1) US20250163076A1 (https=)
EP (1) EP4479405A1 (https=)
JP (1) JP2025506671A (https=)
KR (1) KR20240148351A (https=)
AU (1) AU2023221549A1 (https=)
CA (1) CA3252338A1 (https=)
CL (1) CL2024002409A1 (https=)
CO (1) CO2024011229A2 (https=)
IL (1) IL314902A (https=)
JO (1) JOP20240182A1 (https=)
MX (1) MX2024010134A (https=)
PE (1) PE20242069A1 (https=)
WO (1) WO2023156599A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025262118A1 (en) * 2024-06-20 2025-12-26 Janssen Pharmaceutica Nv Combination therapy using a malt1 inhibitor and a btk inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3794B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
WO2018103060A1 (en) * 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Also Published As

Publication number Publication date
MX2024010134A (es) 2024-08-27
CA3252338A1 (en) 2023-08-24
KR20240148351A (ko) 2024-10-11
EP4479405A1 (en) 2024-12-25
IL314902A (en) 2024-10-01
PE20242069A1 (es) 2024-10-18
JOP20240182A1 (ar) 2024-08-14
CO2024011229A2 (es) 2024-08-30
US20250163076A1 (en) 2025-05-22
WO2023156599A1 (en) 2023-08-24
AU2023221549A1 (en) 2024-10-03
CL2024002409A1 (es) 2025-01-03

Similar Documents

Publication Publication Date Title
JP7425724B2 (ja) Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物及びその誘導体
JP7168149B2 (ja) Ｆｇｆｒ阻害剤としてのピラジン－２（１ｈ）－オン系化合物
KR102693367B1 (ko) Ehmt2 저해제로서의 아민-치환된 헤테로사이클릭 화합물 및 이의 사용 방법
EP3248980B1 (en) Jak inhibitor
ES2587782T3 (es) Síntesis de compuesto antivírico
WO2022266258A1 (en) Compounds and methods for the targeted degradation of irak-4
JP7797486B2 (ja) 新規なｒｈｏ関連タンパク質キナーゼ阻害剤の調製方法およびその調製方法における中間体
WO2025053850A1 (en) Covalent kras-binding compounds for medical treatment
JP2023528394A (ja) 大環状ｊａｋ阻害剤およびその適用
TW202508568A (zh) Ｉｒａｋ４蛋白水解靶向嵌合體
JP2023525933A (ja) Ｒｅｔキナーゼ阻害剤としての化合物およびその応用
JP2025506671A (ja) ブルトン型チロシンキナーゼ阻害剤の合成
KR102412045B1 (ko) 혈액응고인자 Xa 억제제로서의 히드라지드 화합물
JP7068402B2 (ja) チアゾール誘導体の製造方法
CN111718332B (zh) 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
WO2022049253A1 (en) Substituted n-heteroaryl-n-pyridinylacetamides as p2x4 modulators
TW202529754A (zh) Tyk2抑制劑及其用途
JP2026502207A (ja) 硫黄／酸素置換グルタルイミジルイミドイソインドリノン骨格に基づいた化合物及びその応用
CN118715228A (zh) 布鲁顿酪氨酸激酶抑制剂的合成
HK40111046A (zh) 布鲁顿酪氨酸激酶抑制剂的合成
CN117279923A (zh) 六元杂芳并脲环的衍生物及其应用
WO2017213210A1 (ja) 複素環化合物
JP2026513938A (ja) Ｉｒａｋ４ ｐｒｏｔａｃ
CN120787219A (zh) 具有取代的戊二酰亚胺基异吲哚啉酮新颖骨架的化合物及其应用
CA3046864C (en) Cdk4/6 inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260209